The use of PCR technology for detecting minimal residual disease in patients with leukemia
1Fred Hutchinson Cancer Research Center, Seattle, USA 98109-1024, USA. jradich@fhcrc.org
Abstract:
The study of minimal residual disease (MRD) aims to understand the biology and clinical significance of leukemia that persists in patients who are in complete pathologic remission. The detection of MRD most consistently has been associated with subsequent relapse in childhood acute lymphoblastic leukemia (ALL), t(15;17) acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) following marrow transplantation. However, in several settings, MRD has been detected in patients enjoying long-term remission. The study of MRD is thus evolving from identifying patients at high risk of relapse to explaining how leukemia can persist for years in an otherwise "cured" patient.
Insights
Detecting minimal residual disease (MRD) in leukemia patients helps predict relapse. Emerging research explores how leukemia persists long-term in "cured" patients, shifting focus from relapse risk to leukemia biology.
Area of Science:
- Hematology
- Oncology
- Cancer Biology
Background:
- Minimal residual disease (MRD) refers to leukemia cells remaining after treatment.
- MRD detection is a strong predictor of relapse in various leukemia types, including ALL, AML, and CML.
- Current understanding is evolving beyond relapse prediction to explain long-term leukemia persistence.
Purpose of the Study:
- To investigate the biological and clinical significance of minimal residual disease (MRD) in leukemia.
- To understand how leukemia can persist in patients in complete remission.
- To re-evaluate the role of MRD from solely predicting relapse to explaining long-term persistence.
Main Methods:
- Analysis of MRD detection in patients with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).
- Correlation of MRD status with patient outcomes, including relapse and long-term remission.
- Review of existing literature and clinical data on MRD in leukemia.
Main Results:
- MRD detection consistently correlates with relapse risk in specific leukemia subtypes (ALL, t(15;17) AML, CML post-transplant).
- MRD has been observed in patients achieving long-term remission, challenging the sole focus on relapse.
- Evidence suggests leukemia can persist undetected for extended periods in seemingly cured patients.
Conclusions:
- The significance of MRD in leukemia extends beyond relapse prediction.
- Further research is needed to elucidate the mechanisms of leukemia persistence in long-term remission.
- Understanding persistent leukemia is crucial for redefining 'cure' and improving long-term patient management.